Bruce Ashford
Overview
Explore the profile of Bruce Ashford including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
327
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pradhan P, Sharman A, Lacey J, Dwyer P, Hill J, Davis K, et al.
Psychooncology
. 2025 Jan;
34(1):e70056.
PMID: 39794862
Background: The post-treatment survivorship period marks the transition away from acute care and poses distinct challenges for individuals with head and neck cancer (HNC). This can be especially challenging for...
2.
Conley J, Genenger B, Ashford B, Ranson M
Int J Mol Sci
. 2024 Aug;
25(15).
PMID: 39126067
The keratinocyte carcinomas, basal cell carcinoma (BCC), and cutaneous squamous cell carcinoma (cSCC), are the most common cancers in humans. Recently, an increasing body of literature has investigated the role...
3.
Kumari P, Kaur M, Dindhoria K, Ashford B, Amarasinghe S, Thind A
Hum Genet
. 2024 May;
143(9-10):1005-1020.
PMID: 38787419
Long-read single-cell transcriptomics (scRNA-Seq) is revolutionizing the way we profile heterogeneity in disease. Traditional short-read scRNA-Seq methods are limited in their ability to provide complete transcript coverage, resolve isoforms, and...
4.
Conley J, Perry J, Ashford B, Ranson M
Exp Dermatol
. 2024 Apr;
33(4):e15089.
PMID: 38659312
Cutaneous squamous cell carcinoma (cSCC) is the second most common malignancy worldwide, with most deaths caused by locally advanced and metastatic disease. Treatment of resectable metastases is typically limited to...
5.
Curtis K, Clark B, Lam M, Huckle R, Melville G, Binks S, et al.
Emerg Med Australas
. 2024 Mar;
36(4):571-578.
PMID: 38451003
Objective: To reduce perceived unnecessary resource use, we modified our tiered trauma response. If a patient was not physiologically compromised, surgical registrar attendance was not mandated. We investigated the effect...
6.
Perry J, Genenger B, Thind A, Ashford B, Ranson M
Cancers (Basel)
. 2024 Jan;
16(2).
PMID: 38254859
Cutaneous squamous cell carcinoma (cSCC) is a very common skin malignancy with poor prognosis for patients with locally advanced or metastatic cSCC (mcSCC). PI3K/AKT/mTOR and cell cycle signalling pathways are...
7.
Yeo N, Genenger B, Aghmesheh M, Thind A, Napaki S, Perry J, et al.
Cancers (Basel)
. 2023 Oct;
15(20).
PMID: 37894393
Approximately 3-5% of patients with cutaneous squamous cell carcinoma (CSCC) develop advanced disease, accounting for roughly 1% of all cancer deaths in Australia. Immunotherapy has demonstrated significant clinical benefit in...
8.
Ng J, Warwick L, Craft P, Austen L, Ashford B, Gorddard N, et al.
Br J Haematol
. 2023 Aug;
203(3):481-484.
PMID: 37608704
No abstract available.
9.
Gupta R, Selinger C, Ashford B, Chua M, Clark J, Damian D, et al.
Pathology
. 2023 Aug;
55(6):743-759.
PMID: 37573165
Non-melanocytic skin cancers (NMSCs) account for five times the incidence of all other cancers combined and cost US $6 billion annually. These are the most frequent specimens encountered in community...
10.
Genenger B, McAlary L, Perry J, Ashford B, Ranson M
STAR Protoc
. 2023 Jun;
4(2):102331.
PMID: 37300829
Multi-cellular tumor spheroids (MCTS) have found widespread use in pre-clinical research. However, their complex three-dimensional structure makes immunofluorescent staining and imaging challenging. Here, we present a protocol for whole spheroid...